New Accounting Ref Date
Renalytix plc
(“RenalytixTM” or the “Company“)
Change of Accounting Reference Date
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that it has resolved to change the Company’s accounting reference date.
The Company’s financial year‑end will change from 30 June to 31 December.
Accordingly:
• Following the Company’s audited results for the year ended 30 June 2025, the current accounting period has been extended and will now end on 31 December 2026, resulting in an 18‑month accounting period.
• The Company published interim results for the six‑month period ended 31 December 2025 in March 2026.
• The Company will publish unaudited interim results for the 12‑month period ending 30 June 2026 in late October 2026.
• The Company will publish audited accounts for the 18‑month period ending 31 December 2026 no later than 30 June 2027, in accordance with AIM Rule 19.
• Thereafter, the Company will report on a 12‑month financial year ending 31 December, with interim results covering the six months to 30 June each year.
The Board believes that the change in accounting reference date will better align the Company’s financial reporting with its operational and strategic planning cycle. Following the recently announced multi-year partnership with Quest Diagnostics (“Quest”), kidneyintelX.dkd is expected to be available for physician ordering through Quest’s system in the first quarter of 2027. As a result, the Company is increasingly using the calendar year as the basis for forecasting, budgeting, and evaluating commercial performance.
The change to a 31 December year-end will therefore better align the Company’s external financial reporting with its internal budgeting and forecasting processes and the expected timing of the next phase of its commercial growth.
For further information, please contact:
|
Renalytix plc |
||
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) |
Tel: +44 (0)20 3470 0470 |
|
|
David Hignell / Jen Clarke (Corporate Finance) |
|
|
|
Vadim Alexandre (Corporate Broking) |
|
|
|
|
|
|
|
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 5300 |
|
|
Mike Seabrook / Nick Lovering |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
LEI – 213800NTOH3FK3WER551
The person responsible for arranging for the release of this Announcement on behalf of RenalytixTM is James McCullough, CEO.
About kidneyintelX.dkd and RenalytixTM (www.kidneyintelx.com and www.renalytix.com)
RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabledin vitrodiagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. It’s KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States’ and the United Kingdom’s medical systems, affecting approximately 15 million and 8 million people, respectively.
RenalytixTM has been granted FDA authorization and Medicare reimbursement forkidneyintelX.dkdwhich is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.